Delivery Order SPE2DR25D6039-SPE2DR26FJ76X
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL with a ceiling value of $1,132.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set to be completed by October 24, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,142.05. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The contract is scheduled for completion by September 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a biologic...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HUMIRA Pen 40mg/4ml in a quantity of two units. This firm fixed-price delivery order, valued at $22,915.94, represents a competitive award with no set-aside designation and is scheduled for completion by September 9, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab)...
- The Defense Logistics Agency awarded a delivery order valued at $3,776.50 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on July 9, 2025, with completion scheduled for July 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used immunosuppressant biologic medication prescribed for inflammatory conditions...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- The Defense Logistics Agency awarded a delivery order valued at $5,485.29 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 40 mg/0.4 mL. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 31, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication prescribed for autoimmune conditions including...
- The Defense Logistics Agency awarded a delivery order valued at $5,497.68 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication prescribed for various autoimmune conditions including...
- SPE2DR25D6039Indefinite Delivery Contract
- SPE2DR25D6039-SPE2DR26FJ76XDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of HUMIRA (adalimumab) pen 40 mg/0.4 mL injections, with a ceiling value of $1,591.92. This is a firm fixed price delivery order with an ultimate completion date of October 31, 2025, and represents a non-competitive set-aside award. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and other inflammatory conditions, making it a critical pharmaceutical component of federal military and veteran healthcare supply chains. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), a $999,999,999.00 global pharmaceutical prime vendor agreement running through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement through its comprehensive product portfolio spanning brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's IDC with DLA supports military healthcare programs worldwide and enables deliveries to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 10/30/25 |